

Table SI. Treatment regimen, duration and dosage of medication for patients with lupus nephritis before enrollment.

Case s	Sex	Age, years	Glucocorticoid	Immunosuppressant drugs	Treatment duration, months
1	Female	31	Prednisone 30 mg qd	MMF 0.5 g bid, hydroxychloroquine 0.1 g bid	26
2	Female	18	Prednisone 8 mg qd	MMF 0.75 g bid, hydroxychloroquine 0.15 g bid	3
3	Female	14	Prednisone 15 mg qd	Hydroxychloroquine 0.2 g bid, amethopterin 5 mg qw	2
4	Female	23	Prednisone 17.5 mg qd	Hydroxychloroquine 0.2 g bid	7
5	Female	42	Prednisone 8 mg qd	MMF 0.625 g bid, hydroxychloroquine 0.15 g bid	7
6	Female	24	Prednisone 10 mg qd	MMF 0.5 g bid, hydroxychloroquine 0.15 g bid, FK 0.15 mg bid	4
7	Male	83	Prednisone 15 mg qd	Hydroxychloroquine 0.1 g bid	1
8	Female	47	No	MMF 0.5 g bid, hydroxychloroquine 0.1 g bid	12
9	Female	41	Prednisone 2 mg qd	MMF 0.5 g qd, hydroxychloroquine 0.1 g bid	4

	e				
10	Male	72	Prednisone 17.5 mg qd	Hydroxychloroquine 0.1 g bid, total dosage of CYC 2.6 g	1
11	Female	36	Prednisone 50 mg qd	Hydroxychloroquine 0.1 g bid	2
12	Female	45	Prednisone 10 mg qd	Hydroxychloroquine 0.1 g bid	9
13	Female	48	Prednisone 15 mg qd	MMF 0.5 g qd, CsA 50 mg bid	3

MMF, mycophenolate mofetil; FK, tacrolimus; CYC, cyclophosphamide; CsA, cyclosporine; qd, once daily; bid, twice daily; qw, once weekly.

Table SII. Comparison of treatment regiments of patients with lupus nephritis after telitacicept treatment.

Case s	Sex	Age, years	Glucocorticoid reduction		Changes of immunosuppressive drugs		Telitacicept, weeks
			Pre-therapy	Post-therapy	Pre-therapy	Post-therapy	
1	Female	31	Prednisone 30 mg qd	Prednisone 5 mg qd	MMF 0.5 g bid, hydroxychloroquine 0.1 g bid	MMF 0.5 g bid, hydroxychloroquine 0.15 g bid	160 mg qw, 48 weeks
2	Female	18	Prednisone 8 mg qd	Prednisone 2 mg qd	MMF 0.75 g bid, hydroxychloroquine 0.15 g bid	MMF 0.5 g bid, hydroxychloroquine 0.1 g bid, CsA 25 mg bid	160 mg qw, 36 weeks
3	Female	14	Prednisone 15 mg qd	Prednisone 3.3 mg qd	Hydroxychloroquine 0.2 g bid, amethopterin 5 mg qw	No	160 mg qw, 36 weeks
4	Female	23	Prednisone 17.5 mg qd	No	Hydroxychloroquine 0.2 g bid	Hydroxychloroquine 0.2 g bid	160 mg qw, 48 weeks
5	Female	42	Prednisone 8 mg qd	No	MMF 0.625 g bid, hydroxychloroquine	Hydroxychloroquine 0.1 g bid	160 mg qw, 36 weeks

					0.15 g bid		
6	Female	24	Prednisone 10 mg qd	No	MMF 0.5 g bid, hydroxychloroquine 0.15 g bid, FK 0.15 mg bid	Hydroxychloroquine 0.1 g bid, FK 0.1 mg bid	160 mg once monthly, 48 weeks
7	Male	83	Prednisone 15 mg qd	No	Hydroxychloroquine 0.1 g bid	Hydroxychloroquine 0.1 g bid	80 mg qw, 48 weeks
8	Female	47	No	No	MMF 0.5 g bid, hydroxychloroquine 0.1 g bid	Hydroxychloroquine 0.1 g bid	160 mg q2w, 48 weeks
9	Female	41	Prednisone 2 mg qd	No	MMF 0.5 g qd, hydroxychloroquine 0.1 g bid	Hydroxychloroquine 0.1 g bid	160 mg qw, 48 weeks
10	Male	72	Prednisone 17.5 mg qd	Prednisone 10 mg qd	Hydroxychloroquine 0.1 g bid, total dosage of CYC 2.6 g	Hydroxychloroquine 0.1 g bid	160 mg qw, 24 weeks
11	Female	36	Prednisone 50 mg qd	Prednisone 10 mg qd	Hydroxychloroquine 0.1 g bid	Hydroxychloroquine 0.1 g bid	160 mg qw, 12 weeks
12	Female	45	Prednisone 10 mg qd	Prednisone 7.5 mg	Hydroxychloroquine	Hydroxychloroquine	160 mg qw, 12 weeks

	e			qd	e 0.1 g bid	ne 0.1 g bid	weeks
13	Femal e	48	Prednisone 15 mg qd	Prednisone 10 mg qd	MMF 0.5 g qd, CsA 50 mg bid	CsA 50 mg bid	160 mg qw, 12 weeks

MMF, mycophenolate mofetil; FK, tacrolimus; CYC, cyclophosphamide; CsA, cyclosporine; qd, once daily; bid, twice daily; qw, once weekly.

Table SIII. Outcomes of telitacicept in lupus nephritis.

Cases	Sex	Age, years	SLEDAI-2K, score		C3, g/l		C4, g/l		ESR, mm/h		Urinary-protein, g/l		eGFR, ml/min/1.73m ²		SCR, μ mol/l		COVID-19 (all infected) symptoms
			Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post	
1	Female	31	11	8	0.73	0.81	0.23	0.26	22	16	4.27	2.51	45.6	26.8	133	205	Fever
2	Female	18	10	10	0.39	0.97	0.03	0.22	23	7	2.12	0.23	127.8	134.2	58	50	No
3	Female	14	35	10	0.81	0.74	0.12	0.22	28	11	3.21	1.21	10.1	9.5	505	530	Fever
4	Female	23	20	2	1.11	0.79	0.24	0.14	16	15	2.21	1.02	95.1	123.1	75	56	No
5	Female	42	12	2	0.69	0.79	0.09	0.11	6	3	0.15	0.23	110.5	112.6	53	56	No
6	Female	24	20	6	0.63	0.42	0.05	0.04	8	1	4.11	0.15	120.3	118	60	62	No
7	Male	83	12	2	0.84	0.90	0.17	0.20	1	1	0.12	0.18	81.2	74.8	78	80	No
8	Female	47	12	3	0.75	0.80	0.21	0.22	7	10	0.25	0.12	97.3	79.8	64	75	No
9	Female	41	15	2	0.77	0.92	0.15	0.20	13	9	0.33	0.29	110.7	109.2	55	56	No
10	Male	72	16	6	1.07	1.02	0.5	0.45	25	27	3.55	1.67	61.5	67.3	104	96	Fever
11	Female	36	8	2	0.79	1.05	0.16	0.24	26	19	3.4	0.66	119.9	119	47	56	No
12	Female	45	13	6	0.67	0.62	0.18	0.17	2	32	0.17	0.11	116.8	113.9	52	56	No
13	Female	48	14	6	0.81	0.87	0.12	0.16	17	25	0.12	0.08	103	102.2	59	59	No

ESR, erythrocyte sedimentation rate; eGFR, estimated glomerular filtration rate; SCR, serum creatinine; Pre, pre-therapy; Post, post-therapy.

